Will insurance cover a GLP-1 for weight loss?

Sometimes, but the default answer is no, and you should plan around it. By federal law, regular Medicare can’t cover drugs for weight loss, with one temporary exception. Work plans often exclude weight-loss GLP-1s completely. Others cover them only after prior authorization (approval from the plan before it pays).

Whether you are covered depends on your plan. For most working people, it depends on a choice your employer made before you ever asked. Here’s the big picture, and then the exact questions that get you a real answer in one phone call.

Medicare: the law says no, with narrow exceptions

Part D can’t cover drugs prescribed for weight loss. That isn’t a choice some plan made. The law itself excludes them, on the same list that keeps hair-growth and fertility drugs out. No appeal letter changes it.

There’s one exception, and it’s narrow. In SELECT (Lincoff et al., NEJM 2023, n=17,604), brand-name semaglutide (Wegovy) cut major heart events, such as heart attack and stroke, by 20% in relative terms. Everyone in the trial already had heart disease, and none had diabetes. Based on that trial, Wegovy was approved for heart use too. Medicare drug plans can cover it for that specific use when your heart disease is documented. Zepbound is also FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity, so plans can cover it for that use. For weight loss alone, regular Part D still can’t pay.

Since July 2026, there’s also a temporary exception. Medicare’s GLP-1 Bridge program covers Wegovy and the Zepbound KwikPen for $50 a month for some people with Part D. You need a BMI of 35 or higher, or a lower BMI plus certain health problems, like heart failure, kidney disease, or a past heart attack or stroke. Your prescriber has to get approval first and confirm you’re also on a diet and exercise plan. The program is set to run through December 2027. Rules and dates can change, so check Medicare.gov or call 1-800-MEDICARE to see if you qualify.

Medicaid varies by state. A few states cover GLP-1s for obesity, most don’t, and the list changes from year to year.

Your employer decided this before you asked

Coverage through work isn’t really decided by “your insurance company.” Employers choose whether their drug plan includes weight-management drugs as a group. Many leave out the whole group, and the drug’s evidence never enters the decision. That’s why one person pays a small copay while their neighbor, with a card from the same insurer, gets a denial letter pointing to a plan exclusion.

If the whole group is left out, prior authorization and appeals mostly can’t fix it. If it’s covered, you still have to get prior authorization.

What prior authorization actually asks for

Criteria vary by plan, but the pattern is consistent. Most follow the FDA label: a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure or sleep apnea. Many also want proof you tried diet and exercise, often for three to six months. Some make you try an older, cheaper drug first. Renewal is the part people miss. Plans often review again at six or twelve months, and many want to see some weight loss to keep paying. Ask your plan for its exact rule.

Approval doesn’t last forever either. Drug lists reset every January, and a plan that covers Wegovy this year can drop it next year. That’s a health problem too, beyond the paperwork. In SURMOUNT-4 (Aronne et al., JAMA 2024), people taken off brand-name tirzepatide (Zepbound) regained about 14% of their body weight over the next year. Those who stayed on Zepbound lost a further 5.5%. Before you start on insurance, know what it takes to keep the coverage.

Call your plan and ask these five questions

The number is on the back of your card, and you should ask for pharmacy benefits.

1. Is Wegovy or Zepbound on my plan’s drug list (formulary)? At what tier?
2. Does my plan leave out weight-management drugs as a group? Ask even if the drug is on the list. If your employer carved them out, that wins.
3. What are the exact prior-authorization rules? What BMI cutoff, diet program records, or older drugs do I need first?
4. What does renewal require after the first six or twelve months?
5. What will I actually pay each month after my deductible?

Write down the answers and get a reference number. Then run them against the full math, including list prices, deductibles, and cash options, in our GLP-1 cost guide.

Why so many people end up paying cash

Add up the exclusions, the denials, and the yearly fight to keep approval. It’s easy to see why many people decide the fight isn’t worth it. Without coverage, there are still two cash routes. Novo Nordisk and Eli Lilly both sell their brand-name products directly, for well below the pharmacy counter price. That includes the Wegovy pen, the Wegovy pill, and Zepbound pens and vials. The Wegovy, Wegovy pill, and Zepbound pages each list the current price. Compounded semaglutide and tirzepatide are made by LegitScript-verified 503A pharmacies in the U.S. As compounded preparations, they are not FDA-approved, and their prices are on their own treatment pages. No insurance is involved at any step, and FSA and HSA cards are accepted.

Make the ten-minute phone call first, because it ends the guessing. If they say the whole group is excluded, skip the appeal. You’d be arguing medicine against a contract. Price the cash route instead. The five-minute quiz starts that, and a clinician reviews your case within 24 hours. Whatever answer you get holds for this plan year, but not necessarily the next.